Search the Community

Showing results for tags 'ont-380'.



More search options

  • Search By Tags

    Type tags separated by commas.
  • Search By Author

Content Type


Categories

  • Biotech Event Tracker

Forums

  • Biotech Stocks
    • General Biotech Investing Discussion
    • Daily Biotech Stock News
    • Biotech Forecast Course Discussion
  • Clinical, Regulatory and Company Catalysts
    • Event Tracker Discussion
    • Suggest Events to Add to the Event Tracker
  • BiotechForecast.com Site Updates, Announcements, & Questions
    • Site Updates & Announcements

Categories

  • Files
  • Image Processing

Found 1 result

  1. SEATTLE, Aug. 08, 2016 (GLOBE NEWSWIRE) -- Cascadian Therapeutics (NASDAQ:CASC), a clinical-stage biopharmaceutical company, today provided a corporate update and reported financial results for the quarter ended June 30, 2016. "During the second quarter, we continued to accelerate the clinical development of our lead product candidate ONT-380, a promising small molecule for the treatment of advanced, metastatic HER2+ breast cancer," said Scott Myers, President and CEO of Cascadian Therapeutics. "Early clinical results with ONT-380 when combined with T-DM1 or capecitabine have suggested a favorable safety and tolerability profile, systemic activity in advanced disease and the potential to improve outcomes in patients with and without brain metastases. We're looking forward to reporting new data from the ongoing Phase 1b Triplet study expected later this year. In addition, we were granted Fast Track designation from the FDA for ONT-380 in HER2+ metastatic breast cancer."